Dr. Gomella Discusses Interdisiplinary Treatment

Video

Leonard G. Gomella, MD from the Jefferson Kimmel Cancer Center Discusses Interdisiplinary Treatment

Related Videos
Mike Lattanzi, MD, medical oncologist, Texas Oncology
Stephen V. Liu, MD
S. Vincent Rajkumar, MD
Rohan Garje, MD
Jeffrey P. Townsend, PhD
Rohan Garje, MD
Josep Maria Piulats Rodriguez, MD, PhD
Angela Jia, MD, PhD, of University Hospitals
Robert Wang, MD, of Fox Chase Cancer Center
Alexander Kutikov, MD, FACS, of Fox Chase Cancer Center
Related Content
Carlos Barrios, MD

Ribociclib Plus NSAI Maintains Manageable Safety Profile in HR+/HER2– Early Breast Cancer

May 17th 2024
Article
Neeraj Agarwal, MD

FDA Approval Insights: Talazoparib Plus Enzalutamide in HRR Gene–Mutated mCRPC

July 17th 2023
Podcast
Sibylle Loibl, MD, PhD, chair, German Breast Group, chief executive officer, GBG Forschungs GmbH

Addition of Denosumab to Neoadjuvant Chemo Does Not Lead to Significant iDFS Differences in Early Breast Cancer

May 17th 2024
Article
Andrew J. Armstrong, MD, MSc

FDA Approval Insights: Olaparib Plus Abiraterone in BRCA-Mutated mCRPC

June 15th 2023
Podcast
T-DXd in HER2+ Metastatic Breast Cancer | Image Credit: © Axel Kock - stock.adobe.com

T-DXd Maintains Survival Advantage Over Physician’s Choice of Therapy in HER2+ Metastatic Breast Cancer

May 16th 2024
Article
Mafalda Oliveira, MD, PhD

Ipatasertib/Anti-HER2 Therapy Is Safe and Active in PIK3CA-Mutant, HER2+ Advanced Breast Cancer

May 16th 2024
Article